PACB — Pacific Biosciences Of California Cashflow Statement
0.000.00%
Last trade - 00:00
- $986.06m
- $1.25bn
- $200.52m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -84.1 | 29.4 | -181 | -314 | -307 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 1.56 | -13.6 | 135 | 94.6 | 98.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -3 | -2.76 | 21 | -54 | -59 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -78.3 | 19.5 | -111 | -263 | -259 |
Capital Expenditures | -2.84 | -1.04 | -5.93 | -16.9 | -8.84 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 64.9 | -218 | -673 | 133 | 13.4 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 62 | -219 | -679 | 116 | 4.6 |
Financing Cash Flow Items | 18 | 34 | -52.2 | — | -93.8 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 26.5 | 252 | 1,170 | 9.62 | 109 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.3 | 52 | 380 | -138 | -146 |